STOCK TITAN
  1. Home
  2. Sec-filings
  3. GILD
  4. [Form 4] Gilead Sciences Inc Insider Trading Activity

[Form 4] Gilead Sciences Inc Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock GILD logo
Gilead Sciences Inc

NASDAQ:GILD

GILD Rankings

#124 Ranked by Market Cap
#1118 Ranked by Dividends

GILD Latest News

Jul 14, 2025
Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for HIV Prevention at IAS 2025
Jul 9, 2025
Gilead Finalizes Agreement With the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries
Jun 25, 2025
Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
Jun 18, 2025
Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection
Jun 1, 2025
Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025

GILD Latest SEC Filings

Jul 16, 2025
[Form 4] Gilead Sciences Inc Insider Trading Activity
Jul 15, 2025
[144] Gilead Sciences Inc SEC Filing
Jul 15, 2025
[144] Gilead Sciences Inc SEC Filing
Jul 15, 2025
[Form 4] Gilead Sciences Inc Insider Trading Activity
Jul 14, 2025
[144] Gilead Sciences Inc SEC Filing

GILD Stock Data

140.86B
1.24B
0.11%
89.78%
1.81%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States
FOSTER CITY